AZENTA INC (AZTA) Stock Fundamental Analysis
NASDAQ:AZTA - Nasdaq - US1143401024 - Common Stock - Currency: USD
Taking everything into account, AZTA scores 5 out of 10 in our fundamental rating. AZTA was compared to 56 industry peers in the Life Sciences Tools & Services industry. While AZTA has a great health rating, there are worries on its profitability. AZTA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AZTA was profitable.
In the past year AZTA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: AZTA reported negative net income in multiple years.
Of the past 5 years AZTA 4 years had a positive operating cash flow.
1.2 Ratios
AZTA's Return On Assets of -7.93% is fine compared to the rest of the industry. AZTA outperforms 60.71% of its industry peers.
The Return On Equity of AZTA (-9.41%) is better than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.93% | ||
| ROE | -9.41% | ||
| ROIC | N/A |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AZTA has a Gross Margin of 41.65%. This is comparable to the rest of the industry: AZTA outperforms 42.86% of its industry peers.
AZTA's Gross Margin has been stable in the last couple of years.
AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.65% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
2. Health
2.1 Basic Checks
AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AZTA has less shares outstanding than it did 1 year ago.
The number of shares outstanding for AZTA has been reduced compared to 5 years ago.
The debt/assets ratio for AZTA is higher compared to a year ago.
2.2 Solvency
AZTA has an Altman-Z score of 3.84. This indicates that AZTA is financially healthy and has little risk of bankruptcy at the moment.
AZTA has a better Altman-Z score (3.84) than 75.00% of its industry peers.
AZTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.84 |
ROIC/WACCN/A
WACC10.26%
2.3 Liquidity
A Current Ratio of 4.18 indicates that AZTA has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.18, AZTA is doing good in the industry, outperforming 64.29% of the companies in the same industry.
AZTA has a Quick Ratio of 3.78. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.78, AZTA is doing good in the industry, outperforming 66.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.18 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
AZTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 113.64%, which is quite impressive.
Measured over the past years, AZTA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.07% on average per year.
Looking at the last year, AZTA shows a small growth in Revenue. The Revenue has grown by 1.33% in the last year.
The Revenue has been decreasing by -3.41% on average over the past years.
EPS 1Y (TTM)113.64%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%300%
Revenue 1Y (TTM)1.33%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-4.41%
3.2 Future
Based on estimates for the next years, AZTA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.43% on average per year.
Based on estimates for the next years, AZTA will show a small growth in Revenue. The Revenue will grow by 2.23% on average per year.
EPS Next Y25.1%
EPS Next 2Y42.83%
EPS Next 3Y35.14%
EPS Next 5Y29.43%
Revenue Next Year-9.47%
Revenue Next 2Y-2.32%
Revenue Next 3Y0.03%
Revenue Next 5Y2.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 57.36, which means the current valuation is very expensive for AZTA.
The rest of the industry has a similar Price/Earnings ratio as AZTA.
When comparing the Price/Earnings ratio of AZTA to the average of the S&P500 Index (28.22), we can say AZTA is valued expensively.
With a Price/Forward Earnings ratio of 32.23, AZTA can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as AZTA.
When comparing the Price/Forward Earnings ratio of AZTA to the average of the S&P500 Index (20.86), we can say AZTA is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.36 | ||
| Fwd PE | 32.23 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AZTA is valued a bit cheaper than the industry average as 64.29% of the companies are valued more expensively.
AZTA's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 60.3 | ||
| EV/EBITDA | 22.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as AZTA's earnings are expected to grow with 35.14% in the coming years.
PEG (NY)2.29
PEG (5Y)N/A
EPS Next 2Y42.83%
EPS Next 3Y35.14%
5. Dividend
5.1 Amount
No dividends for AZTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.96
+0.73 (+2.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners115.49%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner Change13.48%
Market Cap1.23B
Analysts71.43
Price Target50.32 (86.65%)
Short Float %10.5%
Short Ratio6.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.54%
Min EPS beat(2)37.26%
Max EPS beat(2)71.81%
EPS beat(4)4
Avg EPS beat(4)98.59%
Min EPS beat(4)37.26%
Max EPS beat(4)162.56%
EPS beat(8)7
Avg EPS beat(8)212.82%
EPS beat(12)11
Avg EPS beat(12)159.27%
EPS beat(16)14
Avg EPS beat(16)124.06%
Revenue beat(2)0
Avg Revenue beat(2)-1.39%
Min Revenue beat(2)-1.7%
Max Revenue beat(2)-1.07%
Revenue beat(4)1
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-2.43%
Max Revenue beat(4)1.9%
Revenue beat(8)4
Avg Revenue beat(8)-0.51%
Revenue beat(12)6
Avg Revenue beat(12)-0.88%
Revenue beat(16)7
Avg Revenue beat(16)-11.36%
PT rev (1m)-11.45%
PT rev (3m)-10.57%
EPS NQ rev (1m)1.89%
EPS NQ rev (3m)42.09%
EPS NY rev (1m)0.57%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-3.37%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.36 | ||
| Fwd PE | 32.23 | ||
| P/S | 1.9 | ||
| P/FCF | 60.3 | ||
| P/OCF | 22.61 | ||
| P/B | 0.72 | ||
| P/tB | 1.32 | ||
| EV/EBITDA | 22.61 |
EPS(TTM)0.47
EY1.74%
EPS(NY)0.84
Fwd EY3.1%
FCF(TTM)0.45
FCFY1.66%
OCF(TTM)1.19
OCFY4.42%
SpS14.21
BVpS37.61
TBVpS20.36
PEG (NY)2.29
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.93% | ||
| ROE | -9.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.65% | ||
| FCFM | 3.15% |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
F-Score6
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 39.15% | ||
| Cap/Sales | 5.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 189.73% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.18 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 3.84 |
F-Score6
WACC10.26%
ROIC/WACCN/A
Cap/Depr(3y)77.14%
Cap/Depr(5y)74.64%
Cap/Sales(3y)8.52%
Cap/Sales(5y)9.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)113.64%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%300%
EPS Next Y25.1%
EPS Next 2Y42.83%
EPS Next 3Y35.14%
EPS Next 5Y29.43%
Revenue 1Y (TTM)1.33%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-4.41%
Revenue Next Year-9.47%
Revenue Next 2Y-2.32%
Revenue Next 3Y0.03%
Revenue Next 5Y2.23%
EBIT growth 1Y14.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1016.06%
EBIT Next 3Y152.04%
EBIT Next 5YN/A
FCF growth 1Y103.52%
FCF growth 3Y-48.98%
FCF growth 5Y-28.07%
OCF growth 1Y110.71%
OCF growth 3Y-30.52%
OCF growth 5Y-11.17%